Steven Bloom

Photoredox catalysis has emerged as an attractive tool for medicinal chemistry, streamlining both targeted drug synthesis and late-stage molecular editing. Research in the Bloom group seeks to harness this multifarious platform to address key challenges at the interface of synthetic chemistry and biotechnology.

Specifically, our group is interested in the use of photoredox catalysis for the synthesis of peptide and protein-based therapeutics, marrying the molecular machinery of cells with the chemical prowess of small molecules, to build new therapeutic modalities. Among our current interest are the development of chemical methods for the synthesis of peptibodies, fusion proteins, bispecific antibody constructs, and peptide/protein-based drug conjugates for targeted therapy.

Additionally, our group seeks to develop new cyclization protocols using photoredox catalysis in combination with endogenous peptides to prepare novel pharmaceutical templates and probe molecules.